Cell Therapy Company Announces Approval For Heart Failure Treatment Study
BioCardia's CardiAMP Cell Therapy: A Groundbreaking Development in Heart Failure Treatment.
In a significant development for the field of cardiovascular disease treatment, BioCardia, Inc. (NASDAQ: BCDA), a leader in innovative, autologous cell therapies, announced the Centers for Medicare & Medicaid Services (CMS) approval for its CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study. This breakthrough has the potential to revolutionize the approach to treating heart failure and offers a new ray of hope for the millions affected by this condition. $BioCardia(BCDA.US$
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
